Statins belong to a class of drugs well known for their ability to reduce circulating low-density lipoprotein cholesterol. In addition to cholesterol lowering, they also exhibit potential antiinflammatory and antioxidant properties, suggesting that tissues other than liver may be targeted by statins to exert their beneficial metabolic effects. Adipocytes have received very little attention as a potential target of these drugs, possibly because adipocytes are not a major source of biosynthetic cholesterol. Here, we examine the effects of simvastatin on the secretory pathway, inflammation, and cellular metabolism of adipocytes as well as on whole-body insulin sensitivity. We find that statins have a selective effect on the secretion of the insulin-sensitizing adipokine adiponectin by reducing circulating levels of the highmolecular-weight form of adiponectin specifically with a concomitant increase in intracellular adiponectin levels. However, these effects on adiponectin do not translate into changes in metabolism or whole-body insulin sensitivity, potentially due to additional antiinflammatory properties of statins. In addition,ob/obmicetreatedwithstatinshavereducedadiposityandanalteredultrastructureoftheplasma membrane with respect to caveolar histology. Our data demonstrate that statins have major effects on the cellular physiology of the adipocyte on multiple levels. (Endocrinology 150: 5262-5272, 2009) O ne of the most widely prescribed category of drugs for cholesterol lowering in the United States are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, more commonly known as statins. Statins function by competitively inhibiting the key rate-limiting step in cholesterol biosynthesis: the conversion of HMGCoA to mevalonate. Inhibition of cholesterol biosynthesis results in an up-regulation of low-density lipoprotein (LDL) receptors, thereby contributing to reduced circulating levels of LDL-cholesterol (LDL-C). These reductions in circulating LDL-C range from 20 -60% and are associated with reduced cardiovascular disease and mortality rates (1, 2). Numerous studies have suggested that the timing and magnitude of the clinical benefits of statins cannot be explained entirely by its lipid-lowering properties. Clinical benefits are often observed within 6 months, before significant regression in atherosclerotic plaques. In the last few years, new insights have been obtained on additional mechanisms of statin action. Other effects of statins may include improvements in endothelial dysfunction, increased nitric oxide bioavailability, antioxidant properties, antiinflammatory properties, and stabilization of atherosclerotic plaques (3, 4). Statins are thought to have additional benefits beyond cardiovascular disease, such as in type 2 diabetes, hypertension, dementia, cancer, and bone metabolism (1). This diversity of effects makes it likely that statins can affect numerous cell types and tissues, either through their lipid-lowering properties or through alternative mechanisms.
O
ne of the most widely prescribed category of drugs for cholesterol lowering in the United States are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, more commonly known as statins. Statins function by competitively inhibiting the key rate-limiting step in cholesterol biosynthesis: the conversion of HMGCoA to mevalonate. Inhibition of cholesterol biosynthesis results in an up-regulation of low-density lipoprotein (LDL) receptors, thereby contributing to reduced circulating levels of LDL-cholesterol (LDL-C). These reductions in circulating LDL-C range from 20 -60% and are associated with reduced cardiovascular disease and mortality rates (1, 2) . Numerous studies have suggested that the timing and magnitude of the clinical benefits of statins cannot be explained entirely by its lipid-lowering properties. Clinical benefits are often observed within 6 months, before significant regression in atherosclerotic plaques. In the last few years, new insights have been obtained on additional mechanisms of statin action. Other effects of statins may include improvements in endothelial dysfunction, increased nitric oxide bioavailability, antioxidant properties, antiinflammatory properties, and stabilization of atherosclerotic plaques (3, 4) . Statins are thought to have additional benefits beyond cardiovascular disease, such as in type 2 diabetes, hypertension, dementia, cancer, and bone metabolism (1) . This diversity of effects makes it likely that statins can affect numerous cell types and tissues, either through their lipid-lowering properties or through alternative mechanisms.
The liver is the primary target of statins due to its important role in the regulation of cholesterol biosynthesis and LDL turnover. However, the additional benefits that statins display suggest important effects in nonhepatic tissues and cell types as well. Adipose tissue is a good candidate tissue to further explore statin action due to its unique ability for bulk cholesterol storage (5) . Although most cell types use cholesterol predominantly to maintain the structure of their cell membrane, adipocytes are unique for their storage capacity of very large quantities of cholesterol, accounting for as much as 25% of whole-body cholesterol. Adipocytes have a relatively low de novo cholesterol synthesis rate, accounting for less than 10% of total systemic cholesterol production. Most adipocyte cholesterol is in a free, nonesterified form and is localized to lipid droplets (6) . In addition, the adipocyte plasma membrane is extremely rich in lipid raft and caveolar structures. Both rafts and caveolae are microdomains highly enriched in cholesterol and are very sensitive to even modest changes in cellular cholesterol levels.
Although there have been a number of clinical reports indicating that statins have an effect on insulin sensitivity, this is far from being an accepted fact in the field, with almost an equal number of reports arguing against a direct impact on any parameters with respect to carbohydrate metabolism. Much of the variability is likely due to differences in the type of statins used, length of treatment, and/or differences in patient populations. In addition, many studies examine statin effects using in vitro models, which are not always an accurate reflection of normal physiological conditions in vivo. Therefore, we set out to examine the effects of statins on wild-type and obese mouse models. We chose to use simvastatin, because this is a lipophilic statin, with high rate of absorption, and it also represents one of the more potent statins on the market with respect to LDL-C reductions.
Materials and Methods

Animals
Mice (FVB) were maintained on 12-h light, 12-h dark cycle with ad libitum access to water and standard chow diet (no. 5058; Lab-Diet, Richmond, IN) or high-fat diet (no. D12492-60 kcal% fat, Research Diets Inc., New Brunswick, NJ), as indicated. Both the FVB wild-type and FVB ob/ob mice were bred in-house. During a high-fat diet challenge, wild-type mice were fed high-fat diet pellets for 4 wk. The colony was maintained in a pathogen-free Association for Assessment and Accreditation of Laboratory Animal Care facility at the Albert Einstein College of Medicine under controlled environment settings (22-25 C, 40 -50% humidity). Mice were housed in groups of two to five in filter top cages. All animal experimental protocols were approved by the Institute for Animal Studies of the Albert Einstein College of Medicine or by the Institutional Animal Care and Use Committee of University of Texas Southwestern Medical Center at Dallas.
Statin treatment
Simvastatin was a kind gift from Merck & Co. (Rahway, NJ) and was dissolved in a 0.25% carboxymethylcellulose/PBS solution. Mice were gavaged daily with 40 mg simvastatin/kg body weight. FVB wild-type mice were 8 wk old, and ob/ob mice were 4 wk old upon initiation of a 2-to 4-wk statin treatment, as indicated. Tail venous blood was collected before and after initiation of treatment.
Serum analysis and metabolic assays
Glucose was measured by an oxidase-peroxidase assay (SigmaAldrich, St. Louis, MO). Insulin and leptin were measured with an insulin and leptin ELISA kit, respectively (Millipore, Billerica, MA). Adiponectin and resistin were measured by RIA (Millipore). Triglycerides (Infinity triglyceride kit; Thermo Electron Corp., Bellefonte, PA) and free fatty acids (FFAs) (NEFA C; Wako Pure Chemical, Richmond, VA) were measured by colorimetric assays. IL-6 was measured with an ELISA kit (R&D Systems, Minneapolis, MN).
Oral glucose tolerance test
Mice were fasted 2 h before administration of glucose (2.5 g/kg body weight) by oral gavage. Tail venous blood was collected and assayed for glucose. Mice were denied access to food during the course of the study.
Triglyceride clearance
Mice were fasted for 2 h and given 15 l olive oil per gram body weight by oral gavage. Blood was collected at each time point and assayed for triglyceride and FFAs. Mice were denied access to food during the course of the study.
LPS challenge
Mice were injected ip with LPS (Sigma-Aldrich) at a dose of 0.1 mg/kg body weight. For the LPS challenge time course, blood was collected and assayed for IL-6 (R&D Systems) and serum amyloid A3 (SAA-3). SAA-3 levels were determined by Western blot analysis of 2 l serum with a polyclonal anti-SAA-3 antibody. For examination of adipose-specific inflammation in response to LPS, mice were killed 90 min after LPS injection and tissues were immediately snap-frozen in liquid nitrogen.
␤-Agonist test
Fed mice were injected ip with the ␤3-adrenergic receptor agonist CL 316,243 (Sigma-Aldrich) at a dose of 1 mg/kg body weight. Blood was collected at 0 and 15 min and assayed for FFA and insulin.
Arginine tolerance test
Mice were fasted 16 h and injected ip with arginine (1 mg/g body weight; Sigma-Aldrich). Blood was collected and assayed for insulin.
In vivo insulin signaling
Mice were fasted for 2 h and injected ip with human insulin at a dose of 1U/kg body weight. Mice were killed at 0, 5, or 10 min after injection, and tissues were immediately frozen in liquid nitrogen. Tissues were homogenized in RIPA buffer, supplemented with complete protease inhibitor cocktail and phosphatase inhibitor cocktail (Roche, Indianapolis, IN). The protein lysate was directly analyzed by Western blot with anti-phospho-AKT (Cell Signaling Technology Inc., Beverly, MA) and antiAkt-1 (Santa Cruz Biotechnology Inc., Santa Cruz, CA). Western blot analysis was done using the LI-COR Odyssey infrared imaging system (LI-COR Biotechnology, Lincoln, NE).
Immunoblot analysis
Adipose tissues were homogenized in TNET buffer lacking Triton X-100 (150 mM NaCl, 5 mM EDTA, 50 mM Tris-HCl, pH 7.5), supplemented with complete protease inhibitor cocktail and phosphatase inhibitor cocktail (Roche). This was followed by low-speed centrifugation (3000 ϫ g at 4 C) to remove the fat cake from the top of the tube. Triton X-100 was added to the homogenate for a final concentration of 1%, and the extract was cleared at 20,000 ϫ g for 15 min at 4 C and mixed with 2ϫ Laemmli sample buffer. Protein samples were resolved on 4 -12% Bis-Tris gels, followed by transfer to BA83 nitrocellulose. Blots were probed with various antibodies, as indicated. The anti-caveolin-1 and anti-insulin receptor-␤ antibodies were obtained from Santa Cruz Biotechnology. Bound antibodies were detected with IRDye 800-conjugated antirabbit or IRDye 700-conjugated antimouse secondary antibodies (Rockland, Gilbertsville, PA). Membranes were scanned with the LI-COR Odyssey infrared imaging system, and band intensities were quantified with Odyssey version 1.2 software (LI-COR).
Adiponectin complex distribution analysis
In serum
The complex distribution of adiponectin was determined by separating 15 l mouse serum over a Superdex 200 10/300 GL column (GE Healthcare Bio-Sciences Corp., Piscataway, NJ) using a Biologic Workstation fast-performance liquid chromatography system (Bio-Rad, Hercules, CA). The column was equilibrated in column buffer (25 mM HEPES, 150 mM NaCl, 1 mM CaCl 2 , pH 8.0), and 0.22-ml fractions were collected. Samples (40 l) were collected over the entire elution of adiponectin and incubated with 10 l 5ϫ Laemmli sample buffer, followed by boiling for 5 min. Samples were loaded on a Criterion precast 26-well gel (Bio-Rad) and subjected to immunoblotting using 1:1000 polyclonal anti-adiponectin antibody, followed by incubation with IRDye 800-coupled goat antirabbit secondary antibody (Rockland). The fluorescence signal obtained at 30 kDa was quantified as described above.
In adipose tissue
Intracellular adiponectin complex distribution was determined by velocity sedimentation as previously described (7) . Briefly, 200 g protein lysate was loaded on 5-20% sucrose gradients. After separation, 10 fractions (150 l) were collected and resolved by SDS-PAGE and quantitative Western blotting. Intracellular total adiponectin levels were determined by quantitative Western blotting of the protein lysate used in the complex distribution analysis.
Quantitation of complexes
For each Western blot, the band intensities of each fraction were plotted onto an x-y line graph. The area under the curve for each distinct peak of the high-molecular-weight (HMW), lowmolecular-weight, and trimer form was determined. To calculate the percentage of each complex, the area of each complex was divided by the total area under the curve and multiplied by 100.
Half-life determination of adiponectin
Adiponectin was produced as previously described (7, 8) . Fractions containing HMW adiponectin complexes were pooled for further processing. Mouse IgGs were purchased from SigmaAldrich. HMW adiponectin and IgG were derivatized with the IRDye 800CW and IRDye 700CW N-hydroxysuccinimide ester dyes, respectively, at a dye to protein 1:1 molar ratio according to the manufacturer's instructions (LI-COR). The labeled HMW adiponectin was administered to mice by retroorbital injection at a dose of 0.3 g/g body weight. Blood was collected 5, 30, 60, and 120 min after injection. For analysis of the injected material in plasma, 1 l plasma was mixed with 19 l Tris-buffered saline and 5 l 5ϫ Laemmli buffer. After separation on a 10 -20% Tricine gel (Invitrogen, Carlsbad, CA), the labeled proteins were directly visualized on the LI-COR Odyssey infrared imaging system in the 700-and 800-nm channels by scanning the gels directly without transfer to a membrane. The 32-kDa adiponectin and 50-and 25-kDa IgG heavy and light chain bands were quantified with Odyssey version 2.1 software. After scanning, the gel was stained with Coomassie, and the light chain band was quantified as loading control. Half-life of the respective proteins were calculated as ln (2)/k, where k is the decay constant.
Quantitative real-time PCR analysis
Mice were killed, and tissue was immediately harvested and frozen in liquid nitrogen. RNA was extracted from tissue using TRIzol reagent (Invitrogen), followed by RNA isolation with the QIAGEN (Valencia, CA) RNeasy tissue kit. Total RNA (1 g) was reverse transcribed with Superscript III reverse transcriptase and oligo(dT) 20 (Invitrogen). Quantitative real-time PCR was done using Sybr Green I master mix and was performed in the Roche LightCycler 480. Primers were designed such that one primer spans an intron to prevent amplification of any contaminating genomic DNA, if present. All PCR were normalized to 18S rRNA, unless otherwise indicated. Relative expression levels were calculated by the ⌬⌬Ct method (9) . All primers are listed in supplemental Table 1 (published as supplemental data on The Endocrine Society's Journals Online web site at http://endo.endojournals.org).
Immunohistochemistry and staining procedures
Fresh adipose tissue was fixed in 10% phosphate-buffered formalin overnight. Paraffin wax sections of 5 m were processed for hematoxylin and eosin staining. ImageJ software was used to measure adipocyte area and is represented as average adipocyte area (micrometers). Adipocyte size was measured from four mice per genotype (Ͼ500 cells per genotype). All images were obtained by a Censys cooled CCD camera (Photometrics, Tucson, AZ) on a Zeiss axiophot (Zeiss, Jena, Germany).
Transmission electron microscopy
Fresh adipose tissue was cut into 1-m 2 pieces and fixed overnight in 2% paraformaldehyde, 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer. They were postfixed with 1% osmium tetroxide followed by 1% uranyl acetate, dehydrated through a graded series of ethanol, and embedded in LX112 resin (LADD Research Industries, Williston, VT). Ultrathin sections (80 nm) were cut on a Reichert Ultracut UCT, stained with uranyl acetate followed by lead citrate, and viewed on a JEOL 1200EX transmission electron microscope at 80 kV.
Statistical analysis
Results are presented as means Ϯ SE or the mean. Statistical analysis was performed with the Student's t test or with two-way ANOVA analysis and subsequent Tukey test using GraphPad Prism 5 (San Diego, CA). Significance was accepted at P Ͻ 0.05.
Supplemental data
Details methods for adipocyte differentiation in cell culture, measurement of pancreas insulin content, tissue cholesterol and triglyceride content, and calorimetry can be found in the supplemental data.
Results
Statins selectively alter the release of the HMW form of adiponectin
To determine whether exposure to an HMG-CoA reductase inhibitor has an impact on plasma steady-state levels of the adipocyte-derived factor adiponectin, we used a preclinical model that would also give us the ability to manipulate various parameters. We treated wild-type mice with 40-mpk (milligrams per kilogram of body weight) simvastatin for 2 wk and measured total and HMW levels of adiponectin before and after treatment. We found that statins caused a 40% reduction in the HMW form of adiponectin (Fig. 1A, left) , whereas total adiponectin levels remained unchanged (Fig. 1A, right) . Therefore, statins caused a redistribution of complexes, i.e. a reduction in percentage of HMW levels. The 20-mpk dose also reduced the HMW form but to a lesser degree (data not shown). Therefore, we chose the 40-mpk dose for further study.
To understand the possible causes for this reduction in circulating HMW adiponectin, we examined intracellular levels of adiponectin in adipose tissue. Statin treatment increased the intracellular complex distribution of HMW adiponectin (Fig. 1B, left) . Because intracellular levels of total adiponectin were also not significantly altered (Fig.  1B, right) , this indicates an overall increase in intracellular levels of HMW adiponectin. The increase in intracellular HMW adiponectin occurs without a significant effect on adiponectin mRNA levels (Fig. 1C) . The net level of a protein in circulation is a reflection of the rate at which the protein is secreted vs. the rate of clearance. We therefore examined whether statins have an impact on the half-life of adiponectin in circulation. The clearance rate was determined by following the plasma concentrations of a fluorescently labeled HMW adiponectin in mice and monitoring the rate of fluorescence decay (10) . We found that the clearance rate of HMW adiponectin was similar to that in vehicle-treated mice (Fig. 1D) . Combined, the reduced levels of circulating HMW adiponectin, increased intracellular HMW adiponectin, and unaffected clearance rate of HMW adiponectin all suggest that statins cause a selective secretion defect for HMW adiponectin in adipocytes. In contrast to the effect on HMW adiponectin, statins have no effect on resistin secretion (data not shown). However, leptin secretion is increased, although this in-FIG. 1. Statin treatment causes a secretion defect of the HMW form of adiponectin. A, The HMW complex of adiponectin (left) and total adiponectin (right) were measured in 8-wk-old male wild-type mice treated with 40-mpk simvastatin or vehicle daily for 2 wk. Graphs show the percent change in adiponectin levels after treatment. B, The complex distribution of HMW adiponectin (%HMW) and total adiponectin levels were measured intracellularly in epididymal adipose tissue from statin-or vehicle-treated wild-type mice. C, Adiponectin mRNA expression was measured in epididymal adipose tissue by realtime PCR. Expression levels were normalized to 18S rRNA. D, The halflife of HMW adiponectin was measured in statin-or vehicle-treated wild-type mice by iv injecting mice with fluorescently labeled recombinant HMW adiponectin protein and monitoring its rate of decay. E, Circulating leptin protein levels were measured in statin-or vehicle-treated wild-type mice. Leptin mRNA expression was measured in epididymal adipose tissue of statin-or vehicle-treated wild-type mice by real-time PCR. Expression levels were normalized to 18S rRNA. Results are expressed as mean Ϯ SE; n ϭ 5 mice per group. *, P Ͻ 0.05 by Student's t test. AU, Arbitrary units. crease is likely due to an increase in leptin mRNA expression (Fig. 1E) .
Caveolae morphology is altered by statin treatment
We noticed that the adiponectin secretion defect caused by statins is reminiscent of the situation seen in cav-1-null (Cav1KO) mice. Cav1KO mice have reduced circulating levels of total (11) and HMW adiponectin, despite having normal intracellular levels of both total and HMW adiponectin (Wernstedt, I., and P.E. Scherer, manuscript in preparation). It is not surprising that statins have an effect on caveolae, because it is well known that caveolar raft structures are highly sensitive to changes in cholesterol levels. Cellular caveolin-1 (cav-1) and cholesterol levels are proportional to each other, with cav-1 levels increasing at higher levels of cholesterol (12) . Statin treatment in other cell types can reduce cav-1 levels in addition to cholesterol levels. Surprisingly, our statintreated mice had an almost 2-fold increase in cav-1 protein levels in adipose tissue ( Fig. 2A) . To follow this up at the ultrastructural level, we performed a detailed examination of caveolar structures in adipocytes by visualizing the plasma membrane by transmission electron microscopy (Fig. 2B) . Caveolae typically occur as flask-shaped invaginations of the plasma membrane, although they can also occasionally be found as vesicular structures near the plasma membrane. Transmission electron microscopy reveals that statin treatment does in fact increase the number of caveolae. However, there are fewer invaginated caveolae visible, with the majority of the caveolar structures present as vesicular structures immediately adjacent to the plasma membrane. These effects may be caused by a reduction in endogenous cholesterol synthesis early in the secretory pathway in adipocytes that is locally important in the endoplasmic reticulum but accounts only for a small percentage of total cellular cholesterol. Measurements of cholesterol content of adipose tissue after statin treatment does not reveal any effects on total tissue cholesterol or triglyceride content (Fig. 2C) .
We took advantage of the clearer cellular morphology that 3T3-L1 adipocytes offer compared with primary adipocytes, due to the much smaller lipid droplet sizes. To test whether statin exposure alters the subcellular distribution of cav-1, we treated 3T3-L1 adipocytes with vehicle, statin, or a combination of statin and mevalonate to relieve the inhibition caused by the statin. We stained the cells for cav-1 and adiponectin (Fig. 2D ). Cells treated with vehicle have some cav-1 staining at the plasma membrane as expected, whereas there is also significant intracellular staining. Adiponectin antibodies stain predominantly intracellular compartments, with the bulk of the stain corresponding to the endoplasmic reticulum. Upon statin exposure, neither the cav-1 signal nor
FIG. 2.
Caveolae morphology is altered by statin treatment. A, Cav-1 protein expression in epididymal adipose tissue of statin-or vehicle-treated wild-type mice was determined by western blot analysis and band intensity was quantitated with the LI-COR imaging system (mean Ϯ SE; n ϭ 4 mice per group). *, P Ͻ 0.05 by Student's t test. B, Transmission electron microscopy of epididymal adipose tissue of statin-or vehicle-treated mice. The arrow indicates a representative invaginated caveola, whereas the arrowhead indicates an uninvaginated, vesicle-like caveolar structure. C, Adipocyte cholesterol and triglyceride content were measured in epididymal adipose tissue from statin-or vehicle-treated wild-type mice (mean Ϯ SE; n ϭ 4 mice per group). D, Immunofluorescence staining for cav-1 (left) and adiponectin (middle) in differentiated 3T3-L1 adipocytes. The two stains were overlaid (right). Cav-1 is shown in green and adiponectin in red. On d 6, 3T3-L1 adipocytes were treated with vehicle (control), 10 M statin, or 10 M statin/50 M mevalonate for 24 h before fixation. The upper statin panel represents a more frequently occurring distribution, where most adiponectin is intracellular, whereas the lower statin panel represents a more atypical adipocyte, where most adiponectin is localized to the plasma membrane (n ϭ 3 per treatment).
the adiponectin distribution were significantly affected and remained vastly nonoverlapping (Fig. 2D, upper statin panel) . However, when examining a large number of fields, there were several examples of cells where the adiponectin staining pattern changed and adiponectin is found at or near the plasma membrane (Fig. 2D , lower statin panel). Although it is not possible to quantify this phenomenon because it is not seen in every cell, it is clear that the adiponectin found at the plasma membrane is not located in caveolae because there was little overlap between the two staining patterns. This point is made more clearly in supplemental movies 1 and 2 that moves the plain of focus along the z-axis for a control or statintreated adipocyte and demonstrates that adiponectin and cav-1 do not colocalize at any level. Coincubation of cells with statins and mevalonate (which reconstitutes endogenous cholesterol biosynthesis) looks like vehicle-treated controls (Fig. 2D, bottom) . We conclude that even though statins have an impact on both caveolar structures and HMW adiponectin secretion, we find little physical colocalization of cav-1 and adiponectin.
Statins have no effect on insulin sensitivity Caveolar raft structures play an important role as docking sites for many signaling proteins. The insulin receptor has previously been shown to reside in rafts and critically depends on the integrity of raft structures in adipocytes for its stability (13) . We therefore tested whether the presence of statins has an impact on the insulin sensitivity of mice. Statin treatment of mice on a high-fat diet causes an approximately 75% reduction in insulin receptor expression in adipose tissue (Fig. 3A) . This is consistent with the local depletion of cholesterol, which then has an impact on the stability of the insulin receptor. However, even though the insulin receptor is reduced to a significant extent in adipose tissue, this does not translate into any differences at the level of insulin signaling (Fig. 3B) . After injection of mice with insulin, we monitored the activation of AKT/protein kinase B, a critical downstream mediator of insulin signaling. AKT activation is similar between vehicle-and statintreated mice. This is consistent with the suggestion that as little as 10% of total cellular insulin receptors are required to get activated to get a full insulin response, provided that the intracellular signal transduction components are in place and are not negatively affected (14) . In line with the absence of an impact on cellular insulin sensitivity in adipocytes, we also failed to detect a difference in systemic insulin sensitivity. Basal insulin and glucose, as well as basal triglyceride and FFA levels, do not display any significant differences (Fig.  3C) . Glucose clearance in wild-type mice during unchallenged conditions (data not shown) or a high-fat diet challenge also do not reveal any differences upon exposure of the mice to statins (Fig. 3C) . These findings in rodents are therefore consistent with the clinical data available for statin treatment that fail to detect a significant improvement or deterioration in insulin sensitivity.
Studies have shown that cav1KO mice have a reduced lipolytic response in response to a ␤3-receptor agonist analyzed by Western blot analysis with a specific insulin receptor-␤ antibody, and band intensity was quantitated with the LI-COR imaging system (mean Ϯ SE; n ϭ 4 mice per group). B, Insulin signaling in statin-or vehicle-treated wild-type mice during a high-fat diet challenge (4 wk). Mice were injected with 1 U insulin/kg body weight, and epididymal adipose tissue was collected 0, 5, and 15 min after injection. The phosphorylation state of AKT was determined by Western blotting directly with specific antibodies for phospho-AKT and total AKT levels. Band intensities were quantitated as in A (mean Ϯ SE; n ϭ 3 mice per group). C, Basal levels of circulating insulin, glucose, triglycerides, and FFAs were measured in wild-type mice on 4 wk high-fat diet after a 2-h fast. Glucose levels during an oral glucose tolerance test are shown in the right panel (mean Ϯ SE; n ϭ 5 mice per group). *, P Ͻ 0.05 by Student's t test. AU, Arbitrary units; mEq, milliequivalents.
Endocrinology, December 2009, 150 (12):5262-5272 endo.endojournals.org (15) . Because statins exert a similar effect on adiponectin secretion as does a cav-1-null mutation, we were interested whether the phenotypic similarities extend to lipolysis as well. Upon injection of wild-type mice with ␤3-agonist, the expected rise in FFA levels can be seen for both vehicleand statin-treated mice (Fig. 4A, left) . Furthermore, ␤3-agonist treatment of white adipocytes can also induce a rapid spike in insulin release at the level of the ␤-cell (16). This rapid release of insulin can still be observed in statin-treated mice, albeit at a reduced level (Fig. 4A,  right) , indicating a deficiency in white adipocytes, pancreatic ␤-cells, or a tertiary organ/cell type that is important for this phenomenon. Because arginine acutely stimulates insulin release directly from ␤-cells, we performed an arginine tolerance test to determine whether insulin content/insulin secretion from the pancreas is affected. Stimulation with arginine indicates a rather strong statin effect, dramatically reducing the firstphase insulin release in response to arginine (Fig. 4B ). In addition, measurement of pancreatic insulin content indicates an overall slightly reduced insulin content in statin-treated tissue, even though this effect did not achieve statistical significance (Fig. 4C) .
To expand on the metabolic analysis, we also performed an oral triglyceride challenge. Even though triglyceride and FFA induction occurs at an earlier time point in the statin-treated mice, suggesting a possible increased rate of absorption of lipids (Fig. 4D) , there is only a limited overall effect. Although we have observed increased circulating levels of leptin by statin treatment (Fig. 1E) , this elevation does not have an impact on food intake or body weight of the mice (Fig. 4, E and F) . Combined, it is surprising that despite system-wide changes in multiple cell types, there is very little net effect on any of the systemic metabolic parameters measured.
Statin treatment reduces adiposity of ob/ob mice
To explore the potential impact of statins on obesity, we treated 4-wk-old ob/ob mice with statins. Similar to the results in wild-type mice (Fig. 3C) , statins do not affect systemic insulin sensitivity. Basal levels of insulin, glucose, triglyceride, and FFA, in addition to glucose clearance, are unaffected by statin treatment (Fig. 5A) . Interestingly, we observed that the mice in the statin-treated group gained   FIG. 4 . Statin effects on insulin secretion and lipid metabolism. A, ␤3-Agonist test in statinor vehicle-treated wild-type mice. FFA (left) and insulin (right) levels were measured at 0 and 15 min after injection with the ␤3-adrenergic receptor agonist CL 316,243 (mean Ϯ SE; n ϭ 5 mice per group). *, P Ͻ 0.05 by Student's t test. B, Arginine tolerance test in statin-or vehicle-treated wild-type mice. Mice were fasted for 16 h and injected with arginine, and insulin levels in circulation were measured (mean Ϯ SE; n ϭ 3 mice per group). *, P Ͻ 0.05 by two-way ANOVA. C, Pancreatic insulin content was measured in statin-or vehicletreated wild-type mice (mean Ϯ SE; n ϭ 4 mice per group). *, P Ͻ 0.05 by Student's t-test. D, Serum triglycerides and FFA were measured in statin-or vehicle-treated wild-type mice during a triglyceride challenge (mean Ϯ SE; n ϭ 4 mice per group). *, P Ͻ 0.05 by two-way ANOVA. E and F, Food intake (E) and body weight (F) were measured in statin-or vehicletreated wild-type mice and expressed as food intake per grams body weight (mean Ϯ SE; n ϭ 4 mice per group).
FIG. 5.
Statin treatment reduces adiposity of ob/ob mice. A, Basal levels of circulating insulin, glucose, triglycerides, and FFAs were measured in vehicleand statin-treated ob/ob mice after a 2-h fast. Glucose levels during an oral glucose tolerance test are shown in the right panel (mean Ϯ SE; n ϭ 5 mice per group). B, Body weight was monitored during the course of treatment in 4-wk-old vehicle-or statin-treated ob/ob mice. Results are represented as percent body weight gained during the course of the 2-wk treatment period. C, Body composition analysis was determined in ob/ob mice at the end of the 2-wk treatment, using magnetic resonance imaging (ECHO MRI). less weight during the course of treatment compared with the vehicle-treated group (Fig. 5B) . Body composition analysis reveals that the difference in body weight is due to a reduction in adipose tissue mass (Fig. 5C ). The reduced adiposity in these mice may be due to a reduction in absolute food intake, even though food intake normalized to body weight is unaffected (Fig. 5D ). Careful analysis of adipocyte histology reveals that the size of the adipocytes is reduced (Fig. 5E ). However, this does not translate into any differences in inflammation of the epididymal (Fig. 5F ) or mesenteric (data not shown) adipose tissue depots, as judged by staining for the macrophage cell surface marker F4/80. There are two possible explanations for this effect on adipocyte size and overall adipose tissue mass. The first possibility is that statins may be anti-adipogenic. There is some in vitro evidence for the anti-adipogenic action of statins (17) (18) (19) (20) (21) , and this may also translate into the in vivo setting. An alternative explanation for the reduced adiposity is that statins cause an increase in energy expenditure. Therefore, mice were subject to a metabolic cage study analysis, which demonstrated that statin-treated mice surprisingly have reduced oxygen consumption throughout the light-dark cycle, although there is no change in locomotion (supplemental Fig. S1 , A and C). In addition, statin treatment causes a reduction in their respiratory exchange ratio during the day, indicative of a preferential use of fatty acids as an energy source rather than carbohydrates (supplemental Fig. S1B ). To test whether the in vitro anti-adipogenic effects of statins observed in literature hold up in vivo, we examined the expression of several preadipocyte and adipocyte markers. Surprisingly, we found that the preadipocyte marker pref-1 was reduced in adipose tissue from statin-treated mice, whereas the adipocyte markers adipocyte fatty acidbinding protein (aP2), peroxisome proliferator-activated receptor-␥ (PPAR␥), and sterol regulatory element binding protein-1C (SREBP-1c) were increased (Fig. 5G) . These data suggest that adipocyte differentiation in vivo may actually be increased by statin treatment. Altered levels of adipogenesis during obesity can trigger adverse metabolic changes in the liver, but statin treatment does not affect hepatic triglyceride levels under these conditions (Fig. 5H) .
Statins exert antiinflammatory effects in adipose tissue
In addition to its cholesterol-lowering properties, statins may exert many of their beneficial effects through their antiinflammatory properties. These antiinflammatory properties are predominantly through a direct effect on the liver, as is seen by their ability to reduce systemic levels of the acute-phase reactant protein C-reactive protein (22, 23). We demonstrate here that during a lipopolysaccharide challenge, mice treated with statins display a reduced induction of IL-6 and SAA-3, both of which are inflammatory proteins predominantly secreted by adipose tissue (Fig. 6A) . In further support of the concept that statins reduce systemic inflammation via a reduction in adipose-specific inflammation, mRNA levels of IL-6, TNF-␣, and SAA-3 are specifically reduced in adipose tissue of statin-treated wild-type mice, whereas their levels are unaffected in the liver (Fig. 6B ). These may be direct or indirect effects of statins.
Discussion
Cholesterol plays a critical role in maintaining the proper function of many different cell types. It is an important structural component of cellular membranes and makes substantial contributions toward maintaining the functional integrity of the cell. The plasma membrane also contains regions with a unique lipid and cholesterol composition, known as lipid rafts and caveolae. Caveolae are distinct from lipid rafts due to their expression of cav proteins, which allows the formation of small, bulb-shaped invaginations of the plasma membrane. Cav-1 and -2 are structural and regulatory components of caveolae and are abundantly expressed in adipocytes. Caveolae are implicated in fatty acid transport and are the docking site for many lipid-linked signaling proteins in adipocytes (12, 24 -28). Caveolae are highly susceptible to changes in cho- lesterol. Rothberg et al. (29) demonstrates that exposure of MDCK epithelial cells to cholesterol-binding agents disrupts caveolar structures and that addition of exogenous cholesterol induces caveolae formation. Through the inhibition of cholesterol biosynthesis, statins have also been found to have an inhibitory effect on caveolae formation through reduced cav-1 expression levels (12) . Statins have also been shown to reduce membrane cholesterol levels, resulting in significant changes on the lipid composition of the plasma membrane (30).
Our results demonstrate for the first time that statins can also interfere with caveolar formation in adipocytes. Adipocytes from mice treated with simvastatin have a reduced number of the typical bulb-like caveolar structures and have a buildup of caveolar vesicles near the plasma membrane, suggesting a deficiency in membrane docking. Cav1KO mice have a complete absence of morphologically distinguishable caveolae in adipocytes. They demonstrate an 80% reduction in circulating levels of total adiponectin and have nearly undetectable amounts of the HMW complex of adiponectin despite normal intracellular levels of total and HMW adiponectin. In addition, the transgenic overexpression of adiponectin in mice (AdipoTG) leads to increased cav-1 levels, indicating a positive relationship between cav-1 and adiponectin expression (31). These data suggest a functional connection between caveolae and adiponectin secretion. A disrupted caveolar structure is also likely to be the mechanism leading to reduced secretion of adiponectin in adipocytes from our statin-treated mice. We demonstrate that the HMW form of adiponectin is increased intracellularly in adipose tissue from statin-treated mice, whereas its levels are reduced in circulation. Clinical studies also support this finding that total adiponectin levels are unaffected by statins (32, 33). Our data suggest that the caveolar structures disrupted by simvastatin have a more specific role in the secretion of HMW adiponectin than for the other isoforms.
There have been several reports indicating that statins have inhibitory effects on adipocyte differentiation (17) (18) (19) (20) . However, we do not find that simvastatin interferes with adipogenesis in vivo. Examination of preadipocyte and adipocyte markers in adipose tissue from statintreated ob/ob mice reveals that simvastatin does not inhibit adipogenesis and, in fact, may even increase adipocyte differentiation. The discrepancy between our study and previous studies likely reflects differences between in vitro and in vivo experimental settings. In addition, Nakata et al. (21) demonstrate that statin-induced inhibition of 3T3-L1 differentiation is more effective earlier in the differentiation process, making this less relevant in an obese mouse model, where adipocytes are predominantly in the fully differentiated state at steady state. An alternative explanation is that the mRNA expression levels of these differentiation markers are not an accurate reflection of their activity levels.
In our current studies, we found that statins have a variety of effects in adipose tissue. We demonstrate that although statins have beneficial effects on inflammation in adipose tissue and reduce adipocyte hypertrophy in ob/ob mice, they also have a negative impact on adipose tissue metabolism due to reduced secretion of HMW adiponectin. Combined, these effects result in no net change in insulin sensitivity. However, any effects on inflammation in ob/ob mice cannot be separated from effects on body weight, so this could be an indirect effect. It would be interesting to determine whether the differential effects of statins can be linked to distinct physical properties of this class of drugs. The variety of statins on the market today may provide early hints as to how these specific compounds may differ with respect to their absorption and cholesterol-lowering properties and their effects on adipocytes.
